Abstract:Trastuzumab is the first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, trastuzumab is associated with cardiotoxicity. It manifests with an asymptomatic reduction of left ventricular ejection fraction (LVEF) and is reversible after discontinuation. Trastuzumab-induced new-onset acute decompensated heart failure is rare (0.5%). We report a case of a 54-year-old woman who received anthracycline (idarubicin, accumulated dose 400 mg/m2 doxorubicin equivalent) for her acute promyelocytic leukocyte 10 years ago, had no relevant comorbidities or other pre-existing cardiovascular diseases, had maintained normal cardiac function, presenting with new-onset dyspnea at rest and bilateral lower extremities swelling 12 weeks after receiving trastuzumab induction chemotherapy for her newly diagnosed early stage HER2-positive breast cancer. Chest X-ray showed severe pulmonary edema. Echocardiography revealed diffuse left ventricular hypokinesis with LVEF 5%. After other possible etiology of cardiomyopathy, including ischemia, infection, substance, or radiation, were excluded by extensive cardiomyopathy workup, a diagnosis of trastuzumab-induced cardiotoxicity was established. Trastuzumab was discontinued, and the patient's symptom was improved with furosemide. Guildline-directed medical therapy was gradually maximized over three months. Repeat transthoracic echocardiography (TTE) at one-year follow-up after the initial diagnosis shows LVEF 33%, and the patient was referred to an advanced heart failure clinic. This case report demonstrated a rare catastrophic cardiac toxicity effect of trastuzumab and its potential association with remote exposure to anthracycline. Studies have investigated the cardiotoxicity in the concurrent use of trastuzumab and anthracycline therapy. However, how trastuzumab affected patients who were exposed to anthracycline for more than eight years had remained unreported. To our knowledge, no previous detailed case report has described the same clinical scenario as in this case. The case also demonstrates the limitation of the commonly used cardio-oncology cardiovascular risk assessment tool and highlights the importance of individualized cardiovascular risk stratification when deciding on chemotherapy plans.

Severe thrombocytopenia related to trastuzumab infusion

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment

Acute thrombocytopenia induced by trastuzumab due to complement reaction: A case report

Management of hereditary hemorrhagic telangiectasia-like symptoms induced by trastuzumab emtansine in a breast cancer patient: case report

Trastuzumab-related cardiac events in the treatment of early breast cancer

From 60% to 5% in 12 Weeks: A Trastuzumab-Induced Left Ventricular Ejection Fraction Drop

Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario

Interstitial lung disease associated with trastuzumab monotherapy: A report of 3 cases

Trastuzumab-Induced Early Corneal Melt in HER2-Positive Breast Cancer: A Case Report and Review

Eruptive telangiectasia: a closer look at trastuzumab-emtansine cutaneous complications in breast cancer patients

Trastuzumab-induced hepatotoxicity and analysis of adverse drug reaction: a case report

Autoimmune hypothyroidism and trastuzumab therapy: a rare association

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors

Life-threatening metastasis was suppressed by trastuzumab containing regimen in a patient with Her2-negative breast cancer

Cardiovascular adverse effects associated with the use of anti-HER2 in breast cancer treatment

Monoclonal-induced cardiotoxicity in patients with non-Hodgkin's lymphoma and breast cancer: A retrospective study in an oncology clinic

Potential Impact of Cardiac Dose-Volume on Acute Cardiac Toxicity Following Concurrent Trastuzumab and Radiotherapy.

Trastuzumab and thyroid dysfunction: An association to be aware of

What Powers Trastuzumab's Cardiotoxicity? Decoding Mitochondrial-Related Gene Expression Through Integrative Review and Meta-Analysis in Cardiomyocytes

[Cardiotoxicity from anti-HER-2 therapies in patients with HER-2 positive breast cancer]

Report of Henoch-Schönlein purpura associated with trastuzumab emtansine